NCT04398225View on ClinicalTrials.gov

A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine in Pediatric Subjects With Attention-deficit/Hyperactivity Disorder

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

June 11, 2020

Primary Completion Date

April 1, 2021

Study Completion Date

April 1, 2021

Conditions
Attention Deficit Hyperactivity Disorder
Interventions
DRUG

Centanafadine

Extended release capsule

Trial Locations (1)

33024

For additional information regarding sites, contact 844-687-8522, Hollywood

All Listed Sponsors
lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT04398225 - A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine in Pediatric Subjects With Attention-deficit/Hyperactivity Disorder | Biotech Hunter | Biotech Hunter